Analysis of the predisposing factors for CR-KP infection and comparison of the reinfection rate and the antibiotherapies in the 2 groups were the endpoints.Results: In the first group, age, comorbidity, previous antibiotic use, and nephrostomy tube rates were higher P = 0.015, P = 0.001, P = 0.004, and P
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background/aim: Carbapenem-resistant Klebsiella pneumoniae CR-KP infections encountered in urology patients differentiate from infections caused by other factors, both in respect to prophylaxis and treatment stage, and require a special approach.
📊
Key Findings & Data:We aimed to analyse the predisposing factors and the antibiotherapies for CR-KP infection outbreak in a tertiary urology clinic.Materials and methods: There were 75 patients in the CR-KP positive group Group I and 146 patients in the CR-KP negative group Group II .
💡
Conclusion & Impact:Analysis of the predisposing factors for CR-KP infection and comparison of the reinfection rate and the antibiotherapies in the 2 groups were the endpoints.Results: In the first group, age, comorbidity, previous antibiotic use, and nephrostomy tube rates were higher P = 0.015, P = 0.001, P = 0.004, and P
Background/aim: Carbapenem-resistant Klebsiella pneumoniae CR-KP infections encountered in urology patients differentiate from infections caused by other factors, both in respect to prophylaxis and treatment stage, and require a special approach. We aimed to analyse the predisposing factors and the antibiotherapies for CR-KP infection outbreak in a tertiary urology clinic.Materials and methods: There were 75 patients in the CR-KP positive group Group I and 146 patients in the CR-KP negative group Group II . Analysis of the predisposing factors for CR-KP infection and comparison of the reinfection rate and the antibiotherapies in the 2 groups were the endpoints.Results: In the first group, age, comorbidity, previous antibiotic use, and nephrostomy tube rates were higher P = 0.015, P = 0.001, P = 0.004, and P
KIZILAY, F., ALİYEV, B., ŞİMŞİR, A., KALEMCİ, M. S., KÖSE, T., TAŞBAKAN, M., PULLUKÇU, H. (2020). Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 1, 239–247. https://ajindex.com/articles/113242
Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases 2013
13 (9): 785-796. Doi: 10.1016/S1473-3099(13)70190-7 2. Zarakolu P, Eser OK, Aladag E, Al-Zahrani IA, Day KM et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013. Diagnostic Microbiology and Infectious Disease 2016
85 (4): 466-470. doi: 10.1016/j. diagmicrobio.2016.05.012 3. van Duin D, Doi Y. Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: Are we at the end of the road? Journal of Clinical Microbiology 2015
53 (10): 3116- 7. doi: 10.1128/JCM.01399-15 4. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A et al. Colistin resistance superimposed to endemic carbapenemresistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Eurosurveillance 2014
19 (42). doi: 10.2807/1560-7917.es2014.19.42.20939 5. van Duin D, Cober ED, Richter SS, Perez F, Cline M et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clinical Microbiology and Infection 2014
20 (12): O1117-O1120. doi: 10.1111/1469-0691.12714 6. Cai T, De Nunzio C, Salonia A, Pea F, Mazzei T et al. Urological infections due to multidrug-resistant bacteria: what we need to know? Urologia Journal 2016
83 (1): 21-26. doi: 10.5301/ uro.5000123 7. Samiolo A, Ardizzi E, Ardizzola A, Bianco O, De Luigi AR et al. The San Luigi Gonzaga Hospital experience: improving blood and urine culture preanalytical quality by shared protocols. Microbiologia Medica 2017
32 (2). doi: 10.4081/ mm.2017.6602 8. Bjerklund Johansen TE, Cek M, Naber K, Stratchounski L, Svendsen MV et al. Prevalence of hospital-acquired urinary tract infections in urology departments. European Urology 2007
51 (4): 1100- 1111. doi: 10.1016/j.eururo.2006.08.012 9. Totsika M, Moriel DG, Idris A, Rogers BA, Wurpel DJ et al. Uropathogenic Escherichia coli mediated urinary tract infection. Current Drug Targets 2012
13 (11): 1386-1399. doi: 10.2174/138945012803530206 10. Zalmanovici Trestioreanu A, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Library: Cochrane Reviews 2010 (10): CD007182. doi: 10.1002/14651858. CD007182.pub2 11. Johansen